clinics offering personalized weight loss plans with compounded semaglutide Transition to Branded Weight Loss
Description
22, 2025, the FDA approved Novo Nordisks oral Wegovy 25 mg as the first oral GLP-1 therapy for weight loss
We break down how the triple agonist reshapes appetite and metabolism, plus real Canadian results
The TRIUMPH-4 Phase 3 trial showed higher discontinuation rates (12 to 18%), though this was partly attributed to the study population and instances of perceived excessive weight loss
Regular monitoring helps track progress and identify any concerns early
Hui H, Farilla L, Merkel P, Perfetti R
